Biomind Labs Announces CAD $2.52 Million Private Placement Financing

Executive Summary

• Biomind Labs Inc. announced a non‑brokered private placement of up to 28 million units at C$0.09 per unit, targeting gross proceeds of up to C$2.52 million.
• Each unit consists of one common share and one warrant to purchase an additional common share at C$0.12 for 24 months after closing.
• Net proceeds are earmarked for advancing clinical development programs, regulatory preparation, and general working capital.

Key Details

• Offering Size: Up to 28,000,000 units.
• Price per Unit: C$0.09.
• Gross Proceeds Target: Up to C$2,520,000.
• Unit Composition: 1 common share + 1 common‑share purchase warrant.
• Warrant Terms: Right to acquire one additional common share at C$0.12 per share; exercisable for 24 months post‑closing.
• Expected Closing Date: On or about February 6, 2026, subject to customary closing conditions and regulatory approvals.
• Statutory Hold Period: Securities issued will be subject to a four‑month‑plus‑one‑day hold period from issuance.
• Finder’s Fees: Company may pay fees to eligible finders in accordance with applicable securities laws and Cboe Canada policies.
• Use of Proceeds: Advance clinical development programs, support regulatory preparations, and provide general working capital.
• U.S. Offering Restrictions: Securities are not registered under the U.S. Securities Act and cannot be offered or sold in the United States or to U.S. persons absent an exemption.

Notable Quotes

(No executive quotes were included in the release.)